Page 60 - 2020Taiwan Food and Drug Administration Annual Report

$FKLHYHPHQWV DQG %HQH¿WV
$ FKLHYHPHQWV DQG %HQH¿WV
I. The “Controlled Drugs Review Committee of the Ministry of Health and Welfare” convened
th
th
the 39 and 40 meeting in 2019 and add a total of 30 items to new controlled drugs and active
pharmaceutical ingredients.
,, :H LQYLWHG WKH RI¿FLDO GHOHJDWLRQ DQG H[SHUWV IURP (8 WKH 8QLWHG 6WDWHV -DSDQ DQG 7KDLODQG
to Taiwan (Figure 4-1); for the seminar of “2019 International Conference on Narcotics: Safe
Use and Management.” This is a meaningful and fruitful event for more than 100 attendees of
the medical and public health policy category.
III. In order to prevent drug shortage and to enhance the risk control/ management and the capacity
of production. We stipulated the “Regulations Governing Management of Manufacturing
Schedule 1 and 2 Controlled Drugs Commissioned to Pharmaceutical Firms,” and contacted

the qualified private pharmaceutical/companies to provide those controlled drugs through
public and private sector coordination, in case If necessary.

'JHVSF cc *OUFSOBUJPOBM $POGFSFODF PO /BSDPUJDT 4BGF 6TF BOE .BOBHFNFOU

58